| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta-Lactamases | 10 | 2018 | 59 | 2.120 |
Why?
|
| Plasmids | 9 | 2019 | 275 | 1.690 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2021 | 151 | 1.130 |
Why?
|
| Bacterial Proteins | 9 | 2018 | 901 | 1.080 |
Why?
|
| Enterobacteriaceae | 6 | 2016 | 22 | 1.000 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 6 | 2018 | 83 | 0.860 |
Why?
|
| DNA Ligases | 8 | 2006 | 13 | 0.860 |
Why?
|
| Cross Infection | 7 | 2018 | 155 | 0.850 |
Why?
|
| Fast Foods | 1 | 2024 | 5 | 0.840 |
Why?
|
| Enterobacteriaceae Infections | 5 | 2017 | 25 | 0.820 |
Why?
|
| Colistin | 2 | 2021 | 8 | 0.820 |
Why?
|
| Bacteriological Techniques | 5 | 2016 | 39 | 0.810 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 3 | 2018 | 11 | 0.800 |
Why?
|
| Genome, Bacterial | 4 | 2017 | 144 | 0.790 |
Why?
|
| Saliva | 2 | 2021 | 134 | 0.780 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 7 | 2019 | 53 | 0.710 |
Why?
|
| beta-Lactam Resistance | 4 | 2015 | 13 | 0.700 |
Why?
|
| Sanitary Engineering | 2 | 2018 | 2 | 0.690 |
Why?
|
| Reading | 1 | 2021 | 35 | 0.680 |
Why?
|
| Gene Transfer, Horizontal | 3 | 2019 | 42 | 0.650 |
Why?
|
| Multilocus Sequence Typing | 2 | 2016 | 13 | 0.620 |
Why?
|
| Umbilical Cord | 1 | 2018 | 39 | 0.560 |
Why?
|
| Microbiological Techniques | 2 | 2019 | 25 | 0.540 |
Why?
|
| Klebsiella pneumoniae | 5 | 2019 | 37 | 0.540 |
Why?
|
| Water Microbiology | 1 | 2018 | 13 | 0.540 |
Why?
|
| Molecular Epidemiology | 3 | 2016 | 57 | 0.540 |
Why?
|
| Pandemics | 2 | 2022 | 914 | 0.530 |
Why?
|
| Bacterial Infections | 4 | 2017 | 184 | 0.530 |
Why?
|
| Fetus | 1 | 2018 | 238 | 0.520 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.510 |
Why?
|
| Blood Transfusion | 1 | 2018 | 179 | 0.510 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 661 | 0.500 |
Why?
|
| Infant, Premature | 1 | 2018 | 307 | 0.480 |
Why?
|
| Staphylococcus aureus | 4 | 2017 | 292 | 0.470 |
Why?
|
| Anti-Bacterial Agents | 10 | 2021 | 880 | 0.470 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 38 | 0.450 |
Why?
|
| Hemolysin Proteins | 2 | 2012 | 32 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 341 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 337 | 0.450 |
Why?
|
| DNA Helicases | 7 | 2006 | 93 | 0.450 |
Why?
|
| Mass Screening | 1 | 2021 | 751 | 0.450 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 72 | 0.440 |
Why?
|
| Infection Control | 1 | 2016 | 134 | 0.440 |
Why?
|
| Achievement | 1 | 2014 | 30 | 0.430 |
Why?
|
| Bacterial Toxins | 2 | 2012 | 112 | 0.430 |
Why?
|
| Humans | 54 | 2024 | 98370 | 0.430 |
Why?
|
| Down Syndrome | 1 | 2014 | 54 | 0.430 |
Why?
|
| Motor Skills | 1 | 2014 | 81 | 0.420 |
Why?
|
| Specimen Handling | 3 | 2021 | 113 | 0.410 |
Why?
|
| Bacteria | 3 | 2018 | 546 | 0.410 |
Why?
|
| Yeasts | 1 | 2013 | 50 | 0.400 |
Why?
|
| DNA-Binding Proteins | 8 | 2006 | 1268 | 0.400 |
Why?
|
| Mycoses | 1 | 2013 | 46 | 0.390 |
Why?
|
| Self Care | 1 | 2014 | 188 | 0.390 |
Why?
|
| Klebsiella Infections | 3 | 2019 | 35 | 0.380 |
Why?
|
| Child Development | 1 | 2014 | 179 | 0.370 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2012 | 5 | 0.370 |
Why?
|
| DNA Repair | 8 | 2006 | 363 | 0.350 |
Why?
|
| Hemochromatosis | 1 | 2011 | 12 | 0.340 |
Why?
|
| Yersinia pestis | 1 | 2011 | 24 | 0.340 |
Why?
|
| Th17 Cells | 1 | 2012 | 97 | 0.340 |
Why?
|
| Plague | 1 | 2011 | 27 | 0.340 |
Why?
|
| Host-Pathogen Interactions | 2 | 2014 | 250 | 0.330 |
Why?
|
| Escherichia coli | 4 | 2017 | 572 | 0.330 |
Why?
|
| Acinetobacter Infections | 2 | 2016 | 19 | 0.310 |
Why?
|
| Hospitals | 3 | 2018 | 335 | 0.310 |
Why?
|
| Acinetobacter baumannii | 2 | 2016 | 29 | 0.310 |
Why?
|
| Opportunistic Infections | 1 | 2009 | 57 | 0.290 |
Why?
|
| Histoplasmosis | 1 | 2009 | 29 | 0.290 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2008 | 11 | 0.280 |
Why?
|
| Gram-Negative Bacteria | 2 | 2020 | 37 | 0.280 |
Why?
|
| Hematoma | 1 | 2009 | 106 | 0.280 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2019 | 65 | 0.280 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2019 | 208 | 0.270 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 191 | 0.260 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2018 | 22 | 0.260 |
Why?
|
| Fatal Outcome | 4 | 2019 | 295 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 5 | 2017 | 917 | 0.250 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2017 | 14 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 713 | 0.250 |
Why?
|
| Genetic Therapy | 1 | 2009 | 375 | 0.250 |
Why?
|
| Cell Nucleolus | 1 | 2006 | 25 | 0.240 |
Why?
|
| Carrier State | 2 | 2017 | 40 | 0.240 |
Why?
|
| Health Personnel | 2 | 2021 | 257 | 0.240 |
Why?
|
| Adenosine Triphosphatases | 1 | 2006 | 141 | 0.230 |
Why?
|
| DNA Ligase ATP | 8 | 2006 | 9 | 0.230 |
Why?
|
| Disease Outbreaks | 3 | 2016 | 149 | 0.230 |
Why?
|
| Antigens, Nuclear | 6 | 2001 | 29 | 0.220 |
Why?
|
| Ubiquitin | 1 | 2006 | 95 | 0.220 |
Why?
|
| DNA Damage | 3 | 2006 | 399 | 0.220 |
Why?
|
| Bacterial Typing Techniques | 2 | 2014 | 28 | 0.210 |
Why?
|
| Nutritive Value | 1 | 2024 | 7 | 0.210 |
Why?
|
| Food Handling | 1 | 2024 | 8 | 0.210 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 1019 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2001 | 463 | 0.200 |
Why?
|
| Nasopharynx | 2 | 2021 | 51 | 0.200 |
Why?
|
| Cytomegalovirus | 1 | 2024 | 74 | 0.200 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2022 | 74 | 0.200 |
Why?
|
| Viral Load | 1 | 2024 | 162 | 0.200 |
Why?
|
| Whole Genome Sequencing | 3 | 2019 | 121 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 116 | 0.190 |
Why?
|
| Oxidative Stress | 1 | 2006 | 489 | 0.190 |
Why?
|
| Genes, Bacterial | 3 | 2017 | 150 | 0.180 |
Why?
|
| Intestines | 2 | 2017 | 442 | 0.180 |
Why?
|
| Epidemiological Monitoring | 3 | 2017 | 43 | 0.180 |
Why?
|
| Polymyxin B | 1 | 2021 | 4 | 0.170 |
Why?
|
| Exome | 1 | 2022 | 149 | 0.170 |
Why?
|
| Medical Informatics Applications | 1 | 2021 | 8 | 0.170 |
Why?
|
| Mouth | 1 | 2021 | 53 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 24 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 48 | 0.160 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 31 | 0.160 |
Why?
|
| Recombination, Genetic | 3 | 2000 | 424 | 0.160 |
Why?
|
| Metagenomics | 2 | 2018 | 106 | 0.160 |
Why?
|
| Fetal Death | 1 | 2000 | 55 | 0.160 |
Why?
|
| Cell Line | 5 | 2006 | 2483 | 0.160 |
Why?
|
| Hospices | 1 | 2019 | 8 | 0.150 |
Why?
|
| Cholangiocarcinoma | 1 | 2020 | 89 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2020 | 137 | 0.150 |
Why?
|
| Infant, Newborn | 4 | 2018 | 2551 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 1945 | 0.150 |
Why?
|
| Azabicyclo Compounds | 1 | 2019 | 4 | 0.150 |
Why?
|
| Time Factors | 6 | 2017 | 5577 | 0.150 |
Why?
|
| Ceftazidime | 1 | 2019 | 8 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2018 | 74 | 0.150 |
Why?
|
| Hospice Care | 1 | 2019 | 40 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 59 | 0.150 |
Why?
|
| Sphingomonas | 1 | 2018 | 4 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 889 | 0.140 |
Why?
|
| Virus Inactivation | 1 | 2018 | 4 | 0.140 |
Why?
|
| Adenoviridae Infections | 1 | 2019 | 16 | 0.140 |
Why?
|
| Drug Contamination | 1 | 2019 | 16 | 0.140 |
Why?
|
| Fetoscopy | 1 | 2018 | 9 | 0.140 |
Why?
|
| Constriction | 1 | 2018 | 26 | 0.140 |
Why?
|
| Disease Reservoirs | 1 | 2018 | 24 | 0.140 |
Why?
|
| Granuloma | 1 | 2019 | 65 | 0.140 |
Why?
|
| Diagnostic Errors | 2 | 2024 | 161 | 0.140 |
Why?
|
| Blood Cells | 1 | 2018 | 32 | 0.140 |
Why?
|
| Disinfection | 1 | 2018 | 15 | 0.140 |
Why?
|
| Coinfection | 1 | 2018 | 72 | 0.140 |
Why?
|
| Acute Pain | 1 | 2018 | 19 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2021 | 140 | 0.140 |
Why?
|
| Viruses | 1 | 2018 | 64 | 0.140 |
Why?
|
| Quality Control | 1 | 2018 | 131 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2022 | 606 | 0.130 |
Why?
|
| Infant, Premature, Diseases | 1 | 2018 | 84 | 0.130 |
Why?
|
| Adenoviridae | 1 | 2019 | 341 | 0.130 |
Why?
|
| Chaplaincy Service, Hospital | 1 | 2017 | 5 | 0.130 |
Why?
|
| Enterobacter cloacae | 1 | 2017 | 13 | 0.130 |
Why?
|
| Pain Management | 1 | 2019 | 194 | 0.130 |
Why?
|
| Clergy | 1 | 2017 | 33 | 0.130 |
Why?
|
| Mice | 16 | 2020 | 12735 | 0.130 |
Why?
|
| Female | 11 | 2022 | 51761 | 0.130 |
Why?
|
| Auranofin | 1 | 2016 | 1 | 0.130 |
Why?
|
| Caregivers | 2 | 2019 | 200 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 89 | 0.130 |
Why?
|
| Child, Hospitalized | 1 | 2017 | 38 | 0.120 |
Why?
|
| Hypothermia | 1 | 2016 | 26 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2019 | 250 | 0.120 |
Why?
|
| Prevalence | 2 | 2018 | 1393 | 0.120 |
Why?
|
| Pain Measurement | 1 | 2018 | 402 | 0.120 |
Why?
|
| Germany | 1 | 2016 | 84 | 0.120 |
Why?
|
| Neurons | 5 | 2001 | 1626 | 0.120 |
Why?
|
| Body Temperature | 1 | 2016 | 128 | 0.120 |
Why?
|
| Enterococcus faecium | 1 | 2016 | 33 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 220 | 0.120 |
Why?
|
| Spirituality | 1 | 2017 | 112 | 0.120 |
Why?
|
| Nocardia | 1 | 2016 | 2 | 0.120 |
Why?
|
| Aeromonas hydrophila | 1 | 2016 | 1 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2021 | 450 | 0.120 |
Why?
|
| Nocardia Infections | 1 | 2016 | 4 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 38 | 0.120 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 67 | 0.120 |
Why?
|
| Nuclear Proteins | 7 | 2004 | 755 | 0.120 |
Why?
|
| Telemedicine | 1 | 2019 | 253 | 0.120 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 12 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 85 | 0.110 |
Why?
|
| Liver | 2 | 2011 | 1230 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2016 | 124 | 0.110 |
Why?
|
| Yersinia | 1 | 2015 | 2 | 0.110 |
Why?
|
| Virulence Factors | 2 | 2014 | 117 | 0.110 |
Why?
|
| Yersinia Infections | 1 | 2015 | 5 | 0.110 |
Why?
|
| Shigella | 1 | 2015 | 2 | 0.110 |
Why?
|
| Chronic Pain | 1 | 2018 | 203 | 0.110 |
Why?
|
| Dysentery, Bacillary | 1 | 2015 | 3 | 0.110 |
Why?
|
| Salmonella | 1 | 2015 | 14 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 195 | 0.110 |
Why?
|
| Anal Canal | 1 | 2016 | 94 | 0.110 |
Why?
|
| Salmonella Infections | 1 | 2015 | 19 | 0.110 |
Why?
|
| Classification | 1 | 2015 | 60 | 0.110 |
Why?
|
| Immune Evasion | 1 | 2014 | 37 | 0.110 |
Why?
|
| Male | 12 | 2022 | 47263 | 0.110 |
Why?
|
| Perioperative Care | 1 | 2016 | 196 | 0.110 |
Why?
|
| Pathology, Molecular | 1 | 2014 | 36 | 0.100 |
Why?
|
| Staphylococcal Protein A | 1 | 2014 | 44 | 0.100 |
Why?
|
| Parents | 1 | 2017 | 323 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 826 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 198 | 0.100 |
Why?
|
| Genomics | 2 | 2022 | 903 | 0.100 |
Why?
|
| Neoplasms | 3 | 2019 | 3349 | 0.100 |
Why?
|
| Critical Care | 1 | 2016 | 462 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2013 | 3616 | 0.090 |
Why?
|
| Skin | 1 | 2016 | 591 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2018 | 867 | 0.090 |
Why?
|
| Fibroblasts | 6 | 2001 | 766 | 0.090 |
Why?
|
| Animals | 17 | 2020 | 28981 | 0.090 |
Why?
|
| United States | 6 | 2024 | 8262 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2011 | 11 | 0.090 |
Why?
|
| Translocation, Genetic | 3 | 2001 | 246 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 287 | 0.090 |
Why?
|
| Ferritins | 1 | 2011 | 28 | 0.090 |
Why?
|
| Infant | 2 | 2017 | 3361 | 0.080 |
Why?
|
| Microbiota | 2 | 2016 | 472 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2577 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2018 | 11043 | 0.080 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 100 | 0.080 |
Why?
|
| Autopsy | 1 | 2011 | 131 | 0.080 |
Why?
|
| DNA, Bacterial | 3 | 2017 | 236 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2017 | 4042 | 0.080 |
Why?
|
| Mice, Knockout | 8 | 2011 | 2212 | 0.080 |
Why?
|
| DNA-Activated Protein Kinase | 4 | 2004 | 16 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1785 | 0.080 |
Why?
|
| Research Personnel | 1 | 2011 | 85 | 0.080 |
Why?
|
| Iron | 1 | 2011 | 178 | 0.080 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2011 | 213 | 0.080 |
Why?
|
| Pneumonia | 1 | 2011 | 195 | 0.080 |
Why?
|
| Dependovirus | 1 | 2009 | 38 | 0.070 |
Why?
|
| Retroperitoneal Space | 1 | 2009 | 43 | 0.070 |
Why?
|
| Adult | 7 | 2019 | 29587 | 0.070 |
Why?
|
| Histoplasma | 1 | 2009 | 17 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 2 | 2000 | 110 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 621 | 0.070 |
Why?
|
| Middle Aged | 7 | 2019 | 29532 | 0.070 |
Why?
|
| Blood | 1 | 2008 | 68 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2056 | 0.070 |
Why?
|
| Central Nervous System | 2 | 2000 | 144 | 0.070 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 2 | 1999 | 18 | 0.070 |
Why?
|
| Culture Media | 2 | 2020 | 138 | 0.070 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 2 | 1999 | 29 | 0.070 |
Why?
|
| Cause of Death | 1 | 2009 | 278 | 0.070 |
Why?
|
| Muscles | 1 | 2008 | 179 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 194 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2009 | 426 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2019 | 201 | 0.070 |
Why?
|
| Lymphocytes | 2 | 2000 | 461 | 0.060 |
Why?
|
| Radiography | 1 | 2009 | 763 | 0.060 |
Why?
|
| Phenotype | 4 | 2022 | 2667 | 0.060 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2014 | 107 | 0.060 |
Why?
|
| RecQ Helicases | 1 | 2006 | 7 | 0.060 |
Why?
|
| Child | 2 | 2017 | 7750 | 0.060 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 33 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1568 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 62 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 2897 | 0.060 |
Why?
|
| Cell Cycle | 4 | 2000 | 519 | 0.060 |
Why?
|
| Ku Autoantigen | 6 | 2001 | 15 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 310 | 0.060 |
Why?
|
| Lung | 1 | 2012 | 1408 | 0.060 |
Why?
|
| Adolescent | 2 | 2017 | 10140 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2006 | 520 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2688 | 0.060 |
Why?
|
| Carbapenems | 2 | 2015 | 12 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2014 | 1126 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1290 | 0.050 |
Why?
|
| Enzyme Stability | 1 | 2004 | 49 | 0.050 |
Why?
|
| Gene Rearrangement | 3 | 2000 | 175 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2006 | 615 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 273 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 403 | 0.050 |
Why?
|
| Apoptosis | 5 | 2001 | 1752 | 0.050 |
Why?
|
| Genotype | 2 | 2016 | 1892 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 530 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 165 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2001 | 110 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2001 | 355 | 0.050 |
Why?
|
| Genes, Lethal | 2 | 2000 | 49 | 0.050 |
Why?
|
| Mutagenesis | 2 | 2001 | 195 | 0.040 |
Why?
|
| Chromosome Aberrations | 2 | 2001 | 353 | 0.040 |
Why?
|
| Cellular Senescence | 2 | 2000 | 111 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2004 | 1145 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2001 | 142 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 578 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2021 | 79 | 0.040 |
Why?
|
| Taste Disorders | 1 | 2021 | 11 | 0.040 |
Why?
|
| Ataxia Telangiectasia | 1 | 2001 | 12 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2001 | 278 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 21 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2001 | 218 | 0.040 |
Why?
|
| Oropharynx | 1 | 2020 | 14 | 0.040 |
Why?
|
| Polyethylene Terephthalates | 1 | 2020 | 19 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2008 | 0.040 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 11 | 0.040 |
Why?
|
| Base Sequence | 1 | 2004 | 2224 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 154 | 0.040 |
Why?
|
| Quinine | 1 | 2000 | 8 | 0.040 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2000 | 15 | 0.040 |
Why?
|
| Babesiosis | 1 | 2000 | 4 | 0.040 |
Why?
|
| Clindamycin | 1 | 2000 | 15 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 4818 | 0.040 |
Why?
|
| Antimalarials | 1 | 2000 | 21 | 0.040 |
Why?
|
| Genome | 2 | 2000 | 417 | 0.040 |
Why?
|
| Sarcoma | 1 | 2001 | 222 | 0.040 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1999 | 27 | 0.040 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1999 | 24 | 0.040 |
Why?
|
| Virus Replication | 1 | 2021 | 292 | 0.040 |
Why?
|
| Directed Molecular Evolution | 1 | 2019 | 26 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2000 | 179 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 91 | 0.040 |
Why?
|
| Hospitals, Federal | 1 | 2018 | 1 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 1999 | 122 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 95 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2019 | 122 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 87 | 0.040 |
Why?
|
| Cell Division | 1 | 2000 | 690 | 0.040 |
Why?
|
| Respiratory System | 1 | 2019 | 120 | 0.040 |
Why?
|
| Neonatal Nursing | 1 | 2018 | 2 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 1998 | 72 | 0.040 |
Why?
|
| Water Supply | 1 | 2018 | 65 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 63 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 3032 | 0.030 |
Why?
|
| Nursing Assessment | 1 | 2018 | 20 | 0.030 |
Why?
|
| Gene Targeting | 1 | 1998 | 72 | 0.030 |
Why?
|
| Microscopy | 1 | 2019 | 92 | 0.030 |
Why?
|
| Necrosis | 1 | 2019 | 219 | 0.030 |
Why?
|
| Internet | 1 | 2021 | 359 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 817 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 182 | 0.030 |
Why?
|
| Nanopores | 1 | 2017 | 9 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 150 | 0.030 |
Why?
|
| Genes, MDR | 1 | 2017 | 7 | 0.030 |
Why?
|
| B-Lymphocytes | 3 | 2014 | 731 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 860 | 0.030 |
Why?
|
| Nucleosides | 1 | 2017 | 22 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 86 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2000 | 670 | 0.030 |
Why?
|
| Heart | 1 | 1999 | 527 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 131 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2016 | 19 | 0.030 |
Why?
|
| Software | 1 | 2021 | 697 | 0.030 |
Why?
|
| Biological Transport | 1 | 2017 | 402 | 0.030 |
Why?
|
| Acinetobacter | 1 | 2016 | 4 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 317 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2016 | 48 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 6273 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1999 | 746 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2019 | 572 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1225 | 0.030 |
Why?
|
| Calcium | 1 | 1999 | 1203 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2014 | 15 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1817 | 0.030 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2014 | 27 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2014 | 87 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2014 | 280 | 0.030 |
Why?
|
| Germinal Center | 1 | 2014 | 69 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2014 | 91 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 528 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 390 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 126 | 0.020 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2013 | 44 | 0.020 |
Why?
|
| Germ-Free Life | 1 | 2013 | 88 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 95 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 301 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2017 | 474 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 219 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 118 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 375 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 400 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2013 | 114 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 722 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 977 | 0.020 |
Why?
|
| Symbiosis | 1 | 2013 | 130 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2013 | 234 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 719 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 529 | 0.020 |
Why?
|
| ADAM10 Protein | 1 | 2011 | 8 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2011 | 27 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 525 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2001 | 2858 | 0.020 |
Why?
|
| Epithelium | 1 | 2011 | 316 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 4428 | 0.020 |
Why?
|
| Cadherins | 1 | 2011 | 190 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2792 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 636 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2001 | 1647 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1454 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2678 | 0.020 |
Why?
|
| T-Lymphocytes | 3 | 2001 | 1334 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1419 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2013 | 826 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1133 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 2023 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2381 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2001 | 5 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 85 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 7568 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2001 | 65 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 392 | 0.010 |
Why?
|
| Diencephalon | 1 | 2000 | 6 | 0.010 |
Why?
|
| Babesia | 1 | 2000 | 2 | 0.010 |
Why?
|
| Hematocrit | 1 | 2000 | 68 | 0.010 |
Why?
|
| Antibodies, Protozoan | 1 | 2000 | 47 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 122 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2000 | 93 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 218 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2000 | 220 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2000 | 163 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 464 | 0.010 |
Why?
|
| Creatinine | 1 | 2000 | 313 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1998 | 66 | 0.010 |
Why?
|
| Genes, Essential | 1 | 1998 | 20 | 0.010 |
Why?
|
| Growth | 1 | 1999 | 42 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 317 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 193 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2000 | 243 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1998 | 123 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2001 | 420 | 0.010 |
Why?
|
| Nervous System | 1 | 1999 | 92 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2000 | 765 | 0.010 |
Why?
|
| Thymus Neoplasms | 1 | 1997 | 48 | 0.010 |
Why?
|
| Fetal Growth Retardation | 1 | 1997 | 73 | 0.010 |
Why?
|
| Homeostasis | 1 | 1999 | 474 | 0.010 |
Why?
|
| Body Patterning | 1 | 1998 | 219 | 0.010 |
Why?
|
| Myocardium | 1 | 1999 | 578 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 21844 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 1752 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1999 | 540 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2000 | 573 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 1999 | 568 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 1615 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 804 | 0.010 |
Why?
|